Meningococcal vaccine development: a novel approach.

Area of Science:

• Vaccinology
• Microbiology
• Immunology

Background:

• Neisseria meningitidis causes meningitis worldwide.
• Current capsular polysaccharide (CPS) vaccines are T-cell independent, limiting efficacy in infants and long-term protection.
• Group B meningococci (GBM) are a major cause of disease, but their poorly immunogenic polysialic acid CPS presents a vaccination challenge.

Purpose of the Study:

• To develop a more effective meningococcal vaccine, particularly against serogroup B.
• To enhance immunogenicity and induce bactericidal (BC) antibodies against meningococcal CPS.
• To create a trivalent vaccine covering serogroups A, B, and C.

Main Methods:

• N-propionyl modification of GBM polysaccharide (GBMP) to improve immunogenicity.
• Conjugation of modified GBMP to recombinant GBM class 3 porin (rPorB) via reductive amination.
• Combination with similar CPS-rPorB conjugates for serogroups A and C to form a trivalent vaccine.

Main Results:

• The N-propionyl modification of GBMP enhanced immunogenicity.
• Conjugation to rPorB modulated the immune response, promoting CPS-specific BC antibodies.
• The trivalent A/B/C conjugate vaccine was safe and highly immunogenic in mice and non-human primates.

Conclusions:

• The developed trivalent meningococcal vaccine generates robust, CPS-specific BC antibodies against serogroups A, B, and C.
• This conjugate vaccine strategy shows potential for providing broad, long-lasting protection against meningococcal disease globally.